Mirikizumab: The Ultimate Gut Guardian – Long-Term Results for Ulcerative Colitis and Crohn’s Disease Finally Revealed!
Mirikizumab: The Game-Changer for Inflammatory Bowel Diseases October 28, 2024 INDIANAPOLIS – Eli Lilly and Company At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel urgency. Mirikizumab also helped over 50% of patients with moderately…